SuperworthNU Skin Enterprises profit margin NUS
Gross, operating and net profit as a share of revenue over the last twelve months, from 2016.
- Net margin, 12 months
- −15.7%
- Operating margin, 12 months
- −0.8%
- Net margin on a year earlier
- −21.9 pts
- Peer median
- 7.3%
Over the twelve months to Jun 30, 2026, NU Skin Enterprises kept −15.7% of its revenue as net profit, with an operating margin of −0.8% and a gross margin of 69.2%.
Five years earlier its net margin was 8.4%.
The median for 10 healthcare stocks of a similar size is 7.3%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 10.8% | 4.4% | 69.4% |
| FY2024 | −8.5% | −8.8% | 68.2% |
| FY2023 | 0.4% | 2.5% | 68.9% |
| FY2022 | 4.7% | 5.0% | 71.7% |
| FY2021 | 5.5% | 8.7% | 75.0% |
| FY2020 | 7.4% | 10.0% | 74.5% |
| FY2019 | 7.2% | 11.0% | 76.0% |
| FY2018 | 4.5% | 9.0% | 76.3% |
| FY2017 | 5.7% | 12.0% | 78.0% |
| FY2016 | 6.5% | 10.5% | 77.3% |
| FY2015 | n/a | n/a | n/a |
| FY2014 | n/a | n/a | n/a |
| FY2013 | n/a | n/a | n/a |
| FY2012 | n/a | n/a | n/a |
| FY2011 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −15.7% | −21.9 pts | −0.8% | |
| Q1 FY26 | 3.8% | +6.1 pts | 5.5% | |
| Q4 FY25 | 10.8% | +19.3 pts | 4.4% | |
| Q3 FY25 | 7.0% | +12.8 pts | −0.7% | |
| Q2 FY25 | 6.2% | +14.3 pts | −0.9% | |
| Q1 FY25 | −2.3% | −2.1 pts | −10.1% | |
| Q4 FY24 | −8.5% | −8.9 pts | −8.8% | |
| Q3 FY24 | −5.8% | −8.7 pts | −4.6% | |
| Q2 FY24 | −8.1% | −11.5 pts | −6.9% | |
| Q1 FY24 | −0.2% | −3.9 pts | 2.2% | |
| Q4 FY23 | 0.4% | −4.3 pts | 2.5% | |
| Q3 FY23 | 2.9% | +1.3 pts | 3.0% |
Against its peers
Companies in Healthcare nearest NU Skin Enterprises' size, closest first, today.
| Company | Profit margin |
|---|---|
| NUSNU Skin Enterprises | −15.7% |
| UTMDUtah Medical Products | 29.0% |
| ELMDElectromed | 15.3% |
| NATRNatures Sunshine Products | 3.7% |
| PLXProtalix BioTherapeutics | 23.5% |
| PDEXPro DEX | 17.6% |
| INFUInfuSystem | 6.0% |
| VMDViemed Healthcare | 4.8% |
| EMBCEmbecta | 8.6% |
| ARVNArvinas | 2.9% |
| NRCNRC Health | 4.2% |
| Peer median | 7.3% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on NU Skin Enterprises
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.